TITLE

In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia

AUTHOR(S)
Kaczor, Agnieszka A.; Kȩdzierska, Ewa; Koszła, Oliwia; Targowska-Duda, Katarzyna M.
PUB. DATE
January 2020
SOURCE
Biomolecules (2218-273X);Jan2020, Vol. 10 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Schizophrenia (SZ) is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms, and is not satisfactorily treated by current antipsychotics. Progress in understanding the basic pathomechanism of the disease has been hampered by the lack of appropriate models. In order to develop modern drugs against SZ, effcient methods to study them in in vitro and in vivo models of this disease are required. In this review a short presentation of current hypotheses and concepts of SZ is followed by a description of current progress in the field of SZ experimental models. A critical discussion of advantages and limitations of in vitro models and pharmacological, genetic, and neurodevelopmental in vivo models for positive, negative, and cognitive symptoms of the disease is provided. In particular, this review concerns the important issue of how cellular and animal systems can help to meet the challenges of modeling the disease, which fully manifests only in humans, as experimental studies of SZ in humans are limited. Next, it is emphasized that novel clinical candidates should be evaluated in animal models for treatment-resistant SZ. In conclusion, the plurality of available in vitro and in vivo models is a consequence of the complex nature of SZ, and there are extensive possibilities for their integration. Future development of more effcient antipsychotics reflecting the pleiotropy of symptoms in SZ requires the incorporation of various models into one uniting model of the multifactorial disorder and use of this model for the evaluation of new drugs.
ACCESSION #
141560031

 

Related Articles

  • Review of depot aripiprazole for schizophrenia. Bilal Motiwala, Farha; Stasia Siscoe, Kim; El-Mallakh, Rif S. // Patient Preference & Adherence;2013, Vol. 7, p1181 

    Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will...

  • An Open-Label Study of Aripiprazole for Methamphetamine Induced Psychosis. Sulaiman, Ahmad Hatim; Gill, Jesjeet Singh; Said, Mas Ayu; Habil, Mohamad Hussain; Zainal, Nor Zuraida; Ng Chong Guan // Klinik Psikofarmakoloji Bulteni;Jun2012, Vol. 22 Issue 2, p121 

    An open-label study of aripiprazole for methamphetamine induced psychosis Objective: This study aimed to explore the therapeutic effects and tolerability of aripiprazole in the treatment of psychosis among methamphetamine dependent patients. Methods: This was an open label single arm prospective...

  • Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry. Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X // Neuropsychopharmacology;Sep2014, Vol. 39 Issue 10, p2485 

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with...

  • Independent Nurse: Clinical - Focus - Schizophrenia. Walters, Paul // GP: General Practitioner;3/3/2006, p103 

    The article presents information related to schizophrenia. Schizophrenia is a severe mental illness that commonly starts in early adulthood and runs a relapsing and remitting course. Diagnosis is based on clusters of symptoms being present for a defined period of time, often one month or longer....

  • Epigenetics and Psychiatry. Mahgoub, Melissa; Monteggia, Lisa // Neurotherapeutics;Oct2013, Vol. 10 Issue 4, p734 

    Psychiatric disorders including major depressive disorder, drug addiction, and schizophrenia are debilitating illnesses with a multitude of complex symptoms underlying each of these disorders. In recent years, it has become appreciated that the onset and development of these disorders goes...

  • Dandy-Walker Malformation-Like Condition Revealed by Refractory Schizophrenia: A Case Report and Literature Review. Tréhout, Maxime; Zhang, Norbert; Blouet, Marie; Borha, Alin; Dollfus, Sonia // Neuropsychobiology;2018/2019, Vol. 77 Issue 2, p59 

    Introduction: Dandy-Walker malformation is a rare congenital malformation involving cystic dilatation of the fourth ventricle, enlarged posterior fossa, complete or partial agenesis of the cerebellar vermis, elevated tentorium cerebelli, and hydrocephalus. Previous research highlighted a...

  • Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond. Waddington, John L.; Zhen, Xuechu; O'Tuathaigh, Colm M. P. // Frontiers in Pharmacology;1/29/2020, p1 

    Alongside positive and negative symptomatology, deficits in working memory, attention, selective learning processes, and executive function have been widely documented in schizophrenia spectrum psychosis. These cognitive abnormalities are strongly associated with impairment across multiple...

  • Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia. Ji Sun Kim; Young Joon Kwon; Hwa Young Lee; Ho-Sung Lee; Sungkean Kim; Se-hoon Shim // Clinical Psychopharmacology & Neuroscience;Feb2020, Vol. 18 Issue 1, p127 

    Objective: Mismatch negativity (MMN) is known to be associated with neuro-cognition and functional outcomes. Remission and recovery rates are related to the neuro-cognition of patients with schizophrenia. The present study explored the relationship of MMN with remission in patients with...

  • Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study. Kumar, Subodh; Chaudhury, Suprakash // Industrial Psychiatry Journal;Jan-Jun2014, Vol. 23 Issue 1, p27 

    Background: Negative symptoms and diminished cognitive ability are also considered as core features of schizophrenia. There are many studies in which negative symptoms and cognitive impairments are individually treated with atypical antipsychotic in comparison with either a placebo or a typical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics